Bioptik Technology Incorporation Stock

Equities

4161

TW0004161005

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
34.25 TWD 0.00% Intraday chart for Bioptik Technology Incorporation +0.59% +6.53%

Financials

Sales 2022 768M 23.57M 32.17M Sales 2023 829M 25.43M 34.72M Capitalization 1.7B 52.28M 71.38M
Net income 2022 48M 1.47M 2.01M Net income 2023 85M 2.61M 3.56M EV / Sales 2022 2.13 x
Net Debt 2022 276M 8.46M 11.55M Net Debt 2023 74.28M 2.28M 3.11M EV / Sales 2023 2.15 x
P/E ratio 2022
28.2 x
P/E ratio 2023
19.3 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.62%
More Fundamentals * Assessed data
Dynamic Chart
Bioptik Technology Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bioptik Technology Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bioptik Technology Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Bioptik Technology Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bioptik Technology Incorporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bioptik Technology Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Bioptik Technology Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Bioptik Technology Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Bioptik Technology Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Bioptik Technology Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Bioptik Technology Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Bioptik Technology Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Bioptik Technology Incorporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Bioptik Technology Incorporation Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Bioptik Technology Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 week+0.59%
Current month-4.60%
1 month-6.55%
3 months+7.87%
6 months+14.36%
Current year+6.53%
More quotes
1 week
33.35
Extreme 33.35
34.95
1 month
32.75
Extreme 32.75
38.35
Current year
30.20
Extreme 30.2
39.55
1 year
28.95
Extreme 28.95
41.48
3 years
21.90
Extreme 21.9048
41.48
5 years
21.90
Extreme 21.9048
41.48
10 years
21.90
Extreme 21.9048
123.53
More quotes
Managers TitleAgeSince
Chief Executive Officer - 00-08-20
Director of Finance/CFO - 15-01-08
Investor Relations Contact - 01-04-01
Members of the board TitleAgeSince
Director/Board Member 74 10-11-14
Director/Board Member - 09-06-29
Director/Board Member - 11-10-18
More insiders
Date Price Change Volume
24-04-26 34.25 0.00% 129,295
24-04-25 34.25 +0.44% 87,060
24-04-24 34.1 -0.29% 103,646
24-04-23 34.2 +1.79% 151,969
24-04-22 33.6 -1.32% 109,298

End-of-day quote Taipei Exchange, April 25, 2024

More quotes
BIOPTIK TECHNOLOGY INCORPORATION is principally engaged in the manufacturing and distribution of medical testing products and beauty care products. The Company mainly provides multifunctional detectors of blood sugar, cholesterol and uric acid, multifunctional detectors of blood sugar, cholesterol, uric acid and heme, as well as blood sugar, cholesterol, uric acid and heme testing paper products, among others. The Company distributes its medical equipment under the brand names of Easy Mate and Easy Touch. The Company also offers biological and medical cosmetics, including toning lotions, essences, facial masks and face cleaning products. Its cosmetic products are distributed under the brand name of ACUREAL. The Company distributes its products within the domestic market and to overseas markets.
More about the company